http://www.nejm.org/doi/full/10.1056/NEJMe1600123
These patients need Best Medical Treatment and often they don't get it.
APT
ACE
Statin: atorvastatin
For diabetics
"In conclusion, ACE inhibitors should be given to all type 1 diabetic patients with microalbuminuria or nephropathy, and to type 2 patients with hypertension, microalbuminuria, or existing cardiovascular disease. All diabetic patients with hypertension and left ventricular hypertrophy should have an ARB such as losartan as first-line therapy."
http://www.medscape.com/viewarticle/504039_5
Instead of operating on patients without symptoms verify that the BMT is prescribed and is working:
Non HDL cholesterol
LDL cholesterol
Ambulatory measure of Arterial Pressure
No arrhythmia
Efficient antiplatelet treatment.
More don't be fooled by the medical illusion:
Look at your complications first.
http://www.nejm.org/doi/full/10.1056/NEJMp1516803
Then don't be fooled by mathematics used in statistics
http://jama.jamanetwork.com/article.aspx?articleid=2503156
Are there evidence based indications of revascularization in ACS above 80% with special features?
All those indications are a matter of personalised medicine and very few scientific evidence back such indications. No RCT, only case reports and small series could be taken in account in these cases:
1/ Contralateral thrombosis
2/ Documented non focal symptoms like hemodynamic symptoms correlated with Willis anomalies and brain flow imaging
3/ Progressing stenosis despite BMT above 80% in verified NASCET measurement (angio or angioCT)
4/ Silent emboli without any other cause (heart, aorta, blood)
5/ Focal symptoms of more than 6 months
Keep in mind that those patients are not many perhaps 5%.
To bring a benefit to those patients the vascular team should keep the peri-operative mortality to 0%, the perioperative morbidity inferior to 3% and the perioperative permeability above 98%.
In conclusion ACS patients should be randomized in RCT instead of being operated on without clear benefit.
<3 and="" nbsp="" perioperative="" permeability="" the="">http://www.medpagetoday.com/Blogs/SlowMedicine/57664?xid=nl_mpt_DHE_2016-05-04&eun=g432148d0r3>
https://echo360ess.ohsu.edu:8443/ess/echo/presentation/cd3cace9-a95f-4678-82c1-7db3f21552ba?ec=true
eLife won’t get an impact factor, says Clarivate
Il y a 10 heures
Aucun commentaire:
Enregistrer un commentaire